Ver registro no DEDALUS
Exportar registro bibliográfico



Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy (2008)

  • Authors:
  • USP affiliated authors: TABORDA, CARLOS PELLESCHI - ICB
  • USP Schools: ICB
  • DOI: 10.1007/s11046-007-9056-1
  • Language: Inglês
  • Imprenta:
  • Source:
    • Título do periódico: Mycopathologia
    • ISSN: 0301-486X
    • Volume/Número/Paginação/Ano: v. 165, n. 4-5, p. 341-352, 2008
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s11046-007-9056-1 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: bronze
    Informações sobre o Citescore
  • Título: Mycopathologia

    ISSN: 0301-486X

    Citescore - 2017: 1.75

    SJR - 2017: 0.597

    SNIP - 2017: 0.776

  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    ICB12100021959PC-ICB BMM SEP 2008
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      TRAVASSOS, Luiz R.; RODRIGUES, Elaine G.; IWAI, Leo K.; TABORDA, Carlos Pelleschi. Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy. Mycopathologia, The Hague, v. 165, n. 4-5, p. 341-352, 2008. DOI: 10.1007/s11046-007-9056-1.
    • APA

      Travassos, L. R., Rodrigues, E. G., Iwai, L. K., & Taborda, C. P. (2008). Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy. Mycopathologia, 165( 4-5), 341-352. doi:10.1007/s11046-007-9056-1
    • NLM

      Travassos LR, Rodrigues EG, Iwai LK, Taborda CP. Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy. Mycopathologia. 2008 ; 165( 4-5): 341-352.
    • Vancouver

      Travassos LR, Rodrigues EG, Iwai LK, Taborda CP. Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy. Mycopathologia. 2008 ; 165( 4-5): 341-352.

    Referências citadas na obra
    Rothbard JB. Synthetic peptides as vaccines. Biotechnology 1992;20:451–65.
    Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nature Revs 2007;6:404–14.
    León B, Martínez del Hoyo G, Parrillas V, Vargas HH, Sánchez-Mateos P, Longo N, López-Bravo M, Ardavín C. Dendritic cell differentiation potential of mouse monocytes: monocytes represent immediate precursors of CD8- and CD8+ splenic dendritic cells. Blood 2004;103:2668–76.
    Landsman L, Varol C, Jung S. Distinct differentiation potential of blood monocyte subsets in the lung. J Immunol 2007;178:2000–7.
    Cutler JE, Deepe Jr GS, Klein B. Advances in combating fungal diseases: vaccines on the threshold. Nature Revs 2007;5:13–28.
    Han Y, Riesselman MH, Cutler JE. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect Immun 2000;68:1649–54.
    Zhang MX, Cutler JE, Han Y, Kozel TR. Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Infect Immun 1998;66:6027–9.
    Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, Norelli F, Bellucci C, Polonelli L, Costantino P, Rappuoli R, Cassone A. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005;202:597–606.
    Casadevall A, Pirofski LA. Polysaccharide-containing conjugate vaccines for fungal diseases. Trends Mol Med 2006;12:6–9.
    Travassos LR, Rodrigues ML, Nimrichter L. Antigenic oligosaccharides, structure and immunobiological relevance. In: Verli H (eds) Insights into carbohydrate structure and biological function, Transworld Research Network, Kerala, India; 2006, p. 109–46.
    Jouault T, Fradin C, Dzierszinski F, Borg-Von-Zepelin M, Tomavo S, Corman R, Trinel PA, Kerckaert JP, Poulain D. Peptides that mimic Candida albicans-derived beta-1,2-linked mannosides. Glycobiology 2001;11:693–701.
    Cassone A, Conti S, De Bernardis F, Polonelli L. Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol Today 1997;18:164–9.
    Polonelli L, Magliani W, Conti S, Bracci L, Lozzi L, Neri P, Adriani D, De Bernardis F, Cassone A. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 2003;71:6205–12.
    Cenci E, Bistoni F, Mencacci A, Perito S, Magliani W, Conti S, Polonelli L, Vecchiarelli A. A synthetic peptide as a novel anticryptococcal agent. Cell Microbiol 2004;6:953–61.
    Travassos LR, Silva LS, Rodrigues EG, Conti S, Salati A, Magliani W, Polonelli L. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J␣Antimicrob Chemother 2004;54:956–8.
    De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997;65:3399–405.
    Omaetxebarría MJ, Moragues MD, Elguezabal N, Rodríguez-Alejandre A, Brena S, Schneider J, Polonelli L, Pontón J. Antifungal and antitumor activities of a monoclonal antibody directed against a stress mannoprotein of Candida albicans. Curr Mol Med 2005;5:393–401.
    Brena S, Omaetxebarria MJ, Elguezabal N, Cabezas J, Moragues MD, Ponton J. Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infect Immun 2007;75:3680–2.
    Moragues MD, Omaetxebarria MJ, Elguezabal N, Sevilla MJ, Conti S, Polonelli L, Ponton J. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect Immun 2003;71:5273–9.
    Sevilla MJ, Robledo B, Rementeria A, Moragues MD, Ponton J. A fungicidal monoclonal antibody protects against murine invasive candidiasis. Infect Immun 2006;74:3042–5.
    Oscarson S, Alpe M, Svahnberg P, Nakouzi A, Casadevall A. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucurono xylomannan oligosaccharide structures. Vaccine 2005; 23:3961–72.
    Fleuridor R, Lees A, Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol 2001;166:1087–96.
    Zheng M, Ramsay AJ, Robichaux MB, Norris KA, Kliment C, Crowe C, Rapaka RR, Steele C, McAllister F, Shellito JE, Marrero L, Schwarzenberger P, Zhong Q, Kolls JK. CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 2005; 115:3536–44.
    Scheckelhoff M, Deepe Jr GS. A deficiency in gamma interferon or interleukin-10 modulates T-cell-dependent responses to heat shock protein 60 from Histoplasma capsulatum. Infect Immun 2005;73:2129–34.
    Lin Jr-S, Yang C-W, Wang D-W, Wu-Hsieh BA. Dendritic cells cross-present exogenous fungal antigens to stimulate a protective CD8 T cell response in infection by Histoplasma capsulatum. J Immunol 2005;174:6282–91.
    Wuthrich M, Finkel-Jiminez BE, Klein BS. Interleukin 12 as an adjuvant to WI-1 adhesin immunization augments delayed-type hypersensitivity, shifts the subclass distribution of immunoglobulin G antibodies, and enhances protective immunity to Blastomyces dermatitidis infection. Infect Immun 2000a;68:7172–4.
    Wuthrich M, Filutowicz HI, Klein BS. Mutation of the WI-1 gene yields an attenuated Blastomyces dermatitidis strain that induces host resistance. J Clin Invest 2000b;106: 1381–9.
    Arruda C, Kashino SS, Fazioli RA, Calich VLG. A primary subcutaneous infection with Paracoccidioides brasiliensis leads to immunoprotection or exacerbated disease depending on the route of challenge. Microbes Infect 2007a;9:308–16.
    Arruda C, Vaz CAC, Calich VLG. Aseptic cure of pulmonary paracoccidioidomycosis can be achieved after previous subcutaneous immunization of susceptible but not resistant mice. Microbes Infect 2007b;9:704–13.
    Puccia R, Schenkman S, Gorin PA, Travassos LR. Exocellular components of Paracoccidioides brasiliensis: identification of a specific antigen. Infect Immun 1986;53:199–206.
    Giannini MJ, Bueno JP, Shikanai-Yasuda MA, Stolf AM, Masuda A, Amato Neto V, Ferreira AW. Antibody response to 43 kDa glycoprotein of Paracoccidioides brasiliensis as a marker for the evaluation of patients under treatment. Am J Trop Med Hyg 1990;43:200–6.
    Puccia R, Travassos LR. The 43 kDa glycoprotein from the human pathogen Paracoccidioides brasiliensis and its deglycosylated form: excretion and susceptibility to proteolysis. Arch Biochem Bioph 1991;289:298–302.
    Travassos LR, Taborda CP, Iwai LK, Cunha-Neto E, Puccia R. The gp43 from Paracoccidioides brasiliensis: A major diagnostic antigen and vaccine candidate. In: Domer JE, Kobayashi GS (eds) The mycota XII, human fungal pathogens. Springer-Verlag, Berlin-Heildeberg; 2004, p. 279–96.
    Almeida SR, Moraes JZ, Camargo ZP, Gesztesi JL, Mariano M, Lopes JD. Pattern of immune response to GP43 from Paracoccidioides brasiliensis in susceptible and resistant mice is influenced by antigen-presenting cells. Cell Immunol 1998;190:68–76.
    Ferreira KS, Lopes JD, Almeida SR. Regulation of T helper cell differentiation in vivo by GP43 from Paracoccidioides brasiliensis provided by different antigen-presenting cells. Scand J Immunol 2003;58:290–7.
    Rodrigues EG, Travassos LR. Nature of the reactive epitopes in Paracoccidioides brasiliensis polysaccharide antigen. J Med Vet Mycol 1994;32:77–81.
    Taborda CP, Juliano MA, Puccia R, Franco M, Travassos LR. Mapping of the T-cell epitope in the major 43-kilodalton glycoprotein of Paracoccidioides brasiliensis which induces a Th-1 response protective against fungal infection in BALB/c mice. Infect Immun 1998;66:786–93.
    Travassos LR, Casadevall A, Taborda CP. Immunomodulation and immunoprotection in fungal infections: humoral and cellular immune responses. In: San-Blas G, Calderone RA (eds) Pathogenic fungi: host interactions and emerging strategies for control. Caister Academic Press, Norfolk, England; 2004, p. 241–83.
    Pinto AR, Puccia R, Diniz SN, Franco MF,Travassos LR. DNA-based vaccination against murine paracoccidioidomycosis using the gp43 gene from Paracoccidioides brasiliensis. Vaccine 2000;18:3050–8.
    Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Lont-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Human Mol Gen 1992;1: 363–9.
    Jiang C, Magee DM, Quitugua TN, Cox RA. Genetic vaccination against Coccidioides immitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA. Infect Immun 1999;67:630–5.
    Iwai LK, Yoshida M, Sidney J, Shikanai-Yasuda MA, Goldberg AC, Juliano MA, Hammer J, Juliano L, Sette A, Kalil J, Travassos LR, Cunha-Neto E. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol Med 2003;9:209–19.
    Iwai LK, Yoshida M, Sadahiro A, Robert da Silva W, Marin ML, Goldberg AC, Juliano MA, Juliano L, Shikanai-Yasuda MA, Kalil J, Cunha-Neto E, Travassos LR. T-cell recognition of Paracoccidioides brasiliensis gp43-derived peptides in patients with paracoccidioidomycosis and healthy individuals. Clin Vacc Immunol 2007;14: 474–6.
    Marques AF, da Silva MB, Juliano MA, Travassos LR, Taborda CP. Peptide immunization as an adjuvant to chemotherapy in mice challenged intratracheally with virulent yeast cells of Paracoccidioides brasiliensis. Antimicrob Agents Chemother 2006;50:2814–9.
    Del Negro G, Lacaz CS, Zamith VA, Siqueira AM. General clinical aspects: Polar forms of paracoccidioidomycosis, the disease in childhood. In: Franco M, Lacaz CS, Restrepo-Moreno A, Del Negro G (eds) Paracoccidioidomycosis. CRC Press, Boca Raton, FL; 1994, p. 225–32.
    Taborda CP, Nakaie CR, Cilli EM, Rodrigues EG, Silva LS, Franco MF, Travassos LR. Synthesis and immunological activity of a branched peptide carrying the T-cell epitope of gp43, the major exocellular antigen of Paracoccidioides brasiliensis. Scand J Immunol 2004;59: 58–65.
    Marschutz MK, Zauner W, Mattner F, Otava A, Buschle M, Bernkop-Schnurch A. Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration. Peptides 2002;23:1727–33.
    Mattos Grosso D, de Almeida SR, Mariano M, Lopes JD. Characterization of gp70 and anti-gp70 monoclonal antibodies in Paracoccidioides brasiliensis pathogenesis. Infect Immun 2003;71:6534–42.
    Marques da Silva SH, Queiroz-Telles F, Colombo AL, Blotta MH, Lopes JD, Camargo ZP. Monitoring gp43 antigenemia in paracoccidioidomycosis patients during therapy. J Clin Microbiol 2004;42:2419–24.
    Silva SH, Mattos Grosso D, Lopes JD, Colombo AL, Blotta MH, Queiroz-Telles F, Camargo ZP. Detection of Paracoccidioides brasiliensis gp70 circulating antigen and follow-up of patients undergoing antimycotic therapy. J Clin Microbiol 2004;42:4480–6.